Join
Live feed
·
INSIDERFilingvia Quantisnow
Travere Therapeutics Inc. logo

Chief Research Officer Rote William E. converted options into 4,250 shares and sold $121,434 worth of shares (2,763 units at $43.95) as part of a pre-agreed trading plan, increasing direct ownership by 1% to 115,474 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track TVTX (Travere Therapeutics Inc.) and more on Quantisnow.